{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:31:13Z","timestamp":1791005473134,"version":"4.1.0"},"reference-count":211,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T00:00:00Z","timestamp":1295395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Cell Commun. Signal."],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s12079-011-0117-3","type":"journal-article","created":{"date-parts":[[2011,1,18]],"date-time":"2011-01-18T02:59:50Z","timestamp":1295319590000},"page":"85-99","source":"Crossref","is-referenced-by-count":29,"title":["Breast cancer at bone metastatic sites: recent discoveries and treatment targets"],"prefix":"10.1002","volume":"5","author":[{"given":"Osama","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana V.","family":"Komarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"issue":"3","key":"117_CR1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/1078-0432.1154.11.3","volume":"11","author":"BK Abraham","year":"2005","unstructured":"Abraham BK, Fritz P et al (2005) Prevalence of CD44+\/CD24-\/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11(3):1154\u20131159","journal-title":"Clin Cancer Res"},{"issue":"5","key":"117_CR2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11(5):421\u2013428","journal-title":"Lancet Oncol"},{"issue":"4","key":"117_CR3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1091\/mbc.12.4.863","volume":"12","author":"JA Aguirre-Ghiso","year":"2001","unstructured":"Aguirre-Ghiso JA, Liu D et al (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12(4):863\u2013879","journal-title":"Mol Biol Cell"},{"issue":"8","key":"117_CR4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/CIRCRESAHA.107.172718","volume":"103","author":"A Aicher","year":"2008","unstructured":"Aicher A, Kollet O et al (2008) The Wnt antagonist Dickkopf-1 mobilizes vasculogenic progenitor cells via activation of the bone marrow endosteal stem cell niche. Circ Res 103(8):796\u2013803","journal-title":"Circ Res"},{"issue":"1","key":"117_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","volume":"7","author":"M Akhtari","year":"2008","unstructured":"Akhtari M, Mansuri J et al (2008) Biology of breast cancer bone metastasis. Cancer Biol Ther 7(1):3\u20139","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"117_CR6","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983\u20133988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"117_CR7","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1172\/JCI35711","volume":"118","author":"AO Aliprantis","year":"2008","unstructured":"Aliprantis AO, Ueki Y et al (2008) NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118(11):3775\u20133789","journal-title":"J Clin Invest"},{"issue":"12","key":"117_CR8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1634\/theoncologist.2009-0161","volume":"14","author":"F Andre","year":"2009","unstructured":"Andre F, Xia W et al (2009) CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14(12):1182\u20131188","journal-title":"Oncologist"},{"issue":"1","key":"117_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.23998","volume":"124","author":"J Araujo","year":"2009","unstructured":"Araujo J, Logothetis C (2009) Targeting Src signaling in metastatic bone disease. Int J Cancer 124(1):1\u20136","journal-title":"Int J Cancer"},{"issue":"6","key":"117_CR10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","volume":"36","author":"J Araujo","year":"2010","unstructured":"Araujo J, Logothetis C (2010) Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 36(6):492\u2013500","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"117_CR11","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.4161\/cbt.8.22.9770","volume":"8","author":"JC Araujo","year":"2009","unstructured":"Araujo JC, Poblenz A et al (2009) Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther 8(22):2153\u20132159","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"117_CR12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","volume":"68","author":"AP Armstrong","year":"2008","unstructured":"Armstrong AP, Miller RE et al (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68(1):92\u2013104","journal-title":"Prostate"},{"issue":"19","key":"117_CR13","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-06-0169","volume":"12","author":"M Balic","year":"2006","unstructured":"Balic M, Lin H et al (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12(19):5615\u20135621","journal-title":"Clin Cancer Res"},{"issue":"15","key":"117_CR14","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-07-6849","volume":"68","author":"D Barkan","year":"2008","unstructured":"Barkan D, Kleinman H et al (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68(15):6241\u20136250","journal-title":"Cancer Res"},{"issue":"14","key":"117_CR15","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-09-2356","volume":"70","author":"D Barkan","year":"2010","unstructured":"Barkan D, El Touny LH et al (2010) Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 70(14):5706\u20135716","journal-title":"Cancer Res"},{"issue":"1","key":"117_CR16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12307-009-0019-6","volume":"2","author":"J Barrios","year":"2009","unstructured":"Barrios J, Wieder R (2009) Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. Cancer Microenviron 2(1):33\u201347","journal-title":"Cancer Microenviron"},{"issue":"19","key":"117_CR17","first-page":"5571","volume":"62","author":"MS Bendre","year":"2002","unstructured":"Bendre MS, Gaddy-Kurten D et al (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62(19):5571\u20135579","journal-title":"Cancer Res"},{"key":"117_CR18","doi-asserted-by":"crossref","unstructured":"Bendre M, Gaddy D, et al (2003a) Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res (415 Suppl):S39\u2013S45","DOI":"10.1097\/01.blo.0000093844.72468.f4"},{"issue":"1","key":"117_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S8756-3282(03)00086-3","volume":"33","author":"MS Bendre","year":"2003","unstructured":"Bendre MS, Montague DC et al (2003b) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33(1):28\u201337","journal-title":"Bone"},{"issue":"23","key":"117_CR20","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1158\/0008-5472.CAN-05-2630","volume":"65","author":"MS Bendre","year":"2005","unstructured":"Bendre MS, Margulies AG et al (2005) Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65(23):11001\u201311009","journal-title":"Cancer Res"},{"issue":"9","key":"117_CR21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/cbt.5.9.3306","volume":"5","author":"JR Berenson","year":"2006","unstructured":"Berenson JR, Rajdev L et al (2006) Pathophysiology of bone metastases. Cancer Biol Ther 5(9):1078\u20131081","journal-title":"Cancer Biol Ther"},{"issue":"17","key":"117_CR22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","volume":"353","author":"DA Berry","year":"2005","unstructured":"Berry DA, Cronin KA et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784\u20131792","journal-title":"N Engl J Med"},{"issue":"11","key":"117_CR23","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/1078-0432.CCR-07-4749","volume":"14","author":"FC Bidard","year":"2008","unstructured":"Bidard FC, Vincent-Salomon A et al (2008) Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14(11):3306\u20133311","journal-title":"Clin Cancer Res"},{"issue":"6","key":"117_CR24","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI37480","volume":"119","author":"B Bierie","year":"2009","unstructured":"Bierie B, Chung CH et al (2009) Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119(6):1571\u20131582","journal-title":"J Clin Invest"},{"issue":"1","key":"117_CR25","first-page":"189","volume":"19","author":"HC Blair","year":"2004","unstructured":"Blair HC, Athanasou NA (2004) Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19(1):189\u2013199","journal-title":"Histol Histopathol"},{"issue":"4","key":"117_CR26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","volume":"12","author":"JJ Body","year":"2006","unstructured":"Body JJ, Facon T et al (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12(4):1221\u20131228","journal-title":"Clin Cancer Res"},{"issue":"2","key":"117_CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","volume":"473","author":"BF Boyce","year":"2008","unstructured":"Boyce BF, Xing L (2008) Functions of RANKL\/RANK\/OPG in bone modeling and remodeling. Arch Biochem Biophys 473(2):139\u2013146","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"117_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.scr.2010.04.002","volume":"5","author":"N Brouard","year":"2010","unstructured":"Brouard N, Driessen R et al (2010) G-CSF increases mesenchymal precursor cell numbers in the bone marrow via an indirect mechanism involving osteoclast-mediated bone resorption. Stem Cell Res 5(1):65\u201375","journal-title":"Stem Cell Res"},{"issue":"7","key":"117_CR29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25(7):829\u2013836","journal-title":"J Clin Oncol"},{"issue":"5","key":"117_CR30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","volume":"13","author":"A Brufsky","year":"2008","unstructured":"Brufsky A, Bundred N et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13(5):503\u2013514","journal-title":"Oncologist"},{"issue":"2","key":"117_CR31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9(2):77\u201385","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"117_CR32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","volume":"112","author":"NJ Bundred","year":"2008","unstructured":"Bundred NJ, Campbell ID et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112(5):1001\u20131010","journal-title":"Cancer"},{"issue":"6","key":"117_CR33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdn740","volume":"20","author":"N Cabioglu","year":"2009","unstructured":"Cabioglu N, Sahin AA et al (2009) Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013\u20131019","journal-title":"Ann Oncol"},{"issue":"6960","key":"117_CR34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","volume":"425","author":"LM Calvi","year":"2003","unstructured":"Calvi LM, Adams GB et al (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425(6960):841\u2013846","journal-title":"Nature"},{"issue":"7","key":"117_CR35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","volume":"11","author":"G Carteni","year":"2006","unstructured":"Carteni G, Bordonaro R et al (2006) Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 11(7):841\u2013848","journal-title":"Oncologist"},{"issue":"1\u20132","key":"117_CR36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2009.07.004","volume":"310","author":"S Casimiro","year":"2009","unstructured":"Casimiro S, Guise TA et al (2009) The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 310(1\u20132):71\u201381","journal-title":"Mol Cell Endocrinol"},{"key":"117_CR37","doi-asserted-by":"crossref","unstructured":"Chatterjee M, van Golen KL (2010) Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype. Int J Cancer","DOI":"10.1002\/ijc.25655"},{"issue":"11","key":"117_CR38","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/carcin\/bgp227","volume":"30","author":"YC Chen","year":"2009","unstructured":"Chen YC, Sosnoski DM et al (2009) Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcinogenesis 30(11):1941\u20131948","journal-title":"Carcinogenesis"},{"issue":"4","key":"117_CR39","first-page":"303","volume":"167","author":"LC Chiedozi","year":"1988","unstructured":"Chiedozi LC (1988) Prognostic significance of exclusive skeletal metastases in stage IV primary carcinoma of the breast. Surg Gynecol Obstet 167(4):303\u2013306","journal-title":"Surg Gynecol Obstet"},{"issue":"2","key":"117_CR40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","volume":"10","author":"JM Chirgwin","year":"2000","unstructured":"Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159\u2013178","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"2","key":"117_CR41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/ajcp\/73.2.232","volume":"73","author":"SY Cho","year":"1980","unstructured":"Cho SY, Choi HY (1980) Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. Am J Clin Pathol 73(2):232\u2013234","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"117_CR42","first-page":"557","volume":"26","author":"KA Cho","year":"2010","unstructured":"Cho KA, Joo SY et al (2010) Osteoclast activation by receptor activator of NF-kappaB ligand enhances the mobilization of hematopoietic progenitor cells from the bone marrow in acute injury. Int J Mol Med 26(4):557\u2013563","journal-title":"Int J Mol Med"},{"issue":"3","key":"117_CR43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/jso.2930110303","volume":"11","author":"N Cifuentes","year":"1979","unstructured":"Cifuentes N, Pickren JW (1979) Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol 11(3):193\u2013205","journal-title":"J Surg Oncol"},{"issue":"8","key":"117_CR44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","volume":"24","author":"P Clezardin","year":"2007","unstructured":"Clezardin P, Teti A (2007) Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 24(8):599\u2013608","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"117_CR45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1677\/erc.1.00543","volume":"12","author":"GA Clines","year":"2005","unstructured":"Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12(3):549\u2013583","journal-title":"Endocr Relat Cancer"},{"key":"117_CR46","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/S1462399408000616","volume":"10","author":"GA Clines","year":"2008","unstructured":"Clines GA, Guise TA (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7","journal-title":"Expert Rev Mol Med"},{"issue":"2","key":"117_CR47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10911-010-9173-1","volume":"15","author":"CJ Creighton","year":"2010","unstructured":"Creighton CJ, Chang JC et al (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15(2):253\u2013260","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"117_CR48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1582-4934.2007.00211.x","volume":"12","author":"AK Croker","year":"2008","unstructured":"Croker AK, Allan AL (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 12(2):374\u2013390","journal-title":"J Cell Mol Med"},{"issue":"1","key":"117_CR49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.V99.1.111","volume":"99","author":"XM Dai","year":"2002","unstructured":"Dai XM, Ryan GR et al (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99(1):111\u2013120","journal-title":"Blood"},{"issue":"12","key":"117_CR50","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-10-0100","volume":"70","author":"J Dai","year":"2010","unstructured":"Dai J, Lu Y et al (2010) Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res 70(12):5014\u20135023","journal-title":"Cancer Res"},{"issue":"6","key":"117_CR51","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1083\/jcb.200205014","volume":"159","author":"EH Danen","year":"2002","unstructured":"Danen EH, Sonneveld P et al (2002) The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis. J Cell Biol 159(6):1071\u20131086","journal-title":"J Cell Biol"},{"issue":"10","key":"117_CR52","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.bjc.6600925","volume":"88","author":"C Denoyelle","year":"2003","unstructured":"Denoyelle C, Hong L et al (2003) New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 88(10):1631\u20131640","journal-title":"Br J Cancer"},{"issue":"12","key":"117_CR53","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","volume":"19","author":"IJ Diel","year":"2008","unstructured":"Diel IJ, Jaschke A et al (2008) Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19(12):2007\u20132011","journal-title":"Ann Oncol"},{"issue":"15","key":"117_CR54","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli F, Vermijlen D et al (2007) Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15):7450\u20137457","journal-title":"Cancer Res"},{"issue":"18","key":"117_CR55","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","volume":"13","author":"WC Dougall","year":"1999","unstructured":"Dougall WC, Glaccum M et al (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13(18):2412\u20132424","journal-title":"Genes Dev"},{"issue":"3","key":"117_CR56","first-page":"307","volume":"26","author":"G Facchini","year":"2007","unstructured":"Facchini G, Caraglia M et al (2007) The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res 26(3):307\u2013312","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"117_CR57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","volume":"112","author":"T Fehm","year":"2009","unstructured":"Fehm T, Beck V et al (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112(3):605\u2013609","journal-title":"Gynecol Oncol"},{"key":"117_CR58","doi-asserted-by":"crossref","unstructured":"Ferlay J, H\u00e9ry C, et al (2010) Global burden of breast cancer. Breast Cancer Epidemiology. C. Li, Springer New York, 1\u201319","DOI":"10.1007\/978-1-4419-0685-4_1"},{"issue":"3","key":"117_CR59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","volume":"105","author":"RS Finn","year":"2007","unstructured":"Finn RS, Dering J et al (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319\u2013326","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"117_CR60","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-05-3119","volume":"66","author":"JL Fisher","year":"2006","unstructured":"Fisher JL, Thomas-Mudge RJ et al (2006) Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 66(7):3620\u20133628","journal-title":"Cancer Res"},{"issue":"10","key":"117_CR61","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Lipton A et al (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27(10):1564\u20131571","journal-title":"J Clin Oncol"},{"issue":"11","key":"117_CR62","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.2005.03.9115","volume":"24","author":"JA Foekens","year":"2006","unstructured":"Foekens JA, Atkins D et al (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24(11):1665\u20131671","journal-title":"J Clin Oncol"},{"issue":"41","key":"117_CR63","doi-asserted-by":"crossref","first-page":"31427","DOI":"10.1074\/jbc.M110.114496","volume":"285","author":"JE Fong","year":"2010","unstructured":"Fong JE, Le Nihouannen D et al (2010) Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase. J Biol Chem 285(41):31427\u201331434","journal-title":"J Biol Chem"},{"issue":"2","key":"117_CR64","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbrc.2004.05.033","volume":"319","author":"M Gallet","year":"2004","unstructured":"Gallet M, Sevenet N et al (2004) Breast cancer cell line MDA-MB 231 exerts a potent and direct anti-apoptotic effect on mature osteoclasts. Biochem Biophys Res Commun 319(2):690\u2013696","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"117_CR65","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s10495-006-9507-z","volume":"11","author":"M Gallet","year":"2006","unstructured":"Gallet M, Mentaverri R et al (2006) Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. Apoptosis 11(11):1909\u20131921","journal-title":"Apoptosis"},{"issue":"27","key":"117_CR66","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/138161210793563554","volume":"16","author":"M Gatien","year":"2010","unstructured":"Gatien M, Benjamin O et al (2010) Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des 16(27):2981\u20132987","journal-title":"Curr Pharm Des"},{"issue":"7","key":"117_CR67","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B et al (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25(7):820\u2013828","journal-title":"J Clin Oncol"},{"issue":"9","key":"117_CR68","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840\u2013849","journal-title":"Lancet Oncol"},{"issue":"7","key":"117_CR69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679\u2013691","journal-title":"N Engl J Med"},{"issue":"7","key":"117_CR70","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","volume":"98","author":"TA Guise","year":"1996","unstructured":"Guise TA, Yin JJ et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98(7):1544\u20131549","journal-title":"J Clin Invest"},{"issue":"20 Pt 2","key":"117_CR71","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","volume":"12","author":"TA Guise","year":"2006","unstructured":"Guise TA, Mohammad KS et al (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20 Pt 2):6213s\u20136216s","journal-title":"Clin Cancer Res"},{"issue":"2","key":"117_CR72","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2008.03.026","volume":"43","author":"Y Guo","year":"2008","unstructured":"Guo Y, Tiedemann K et al (2008) Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone 43(2):386\u2013393","journal-title":"Bone"},{"issue":"1","key":"117_CR73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57\u201370","journal-title":"Cell"},{"issue":"2","key":"117_CR74","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-07-1189","volume":"14","author":"S Hassan","year":"2008","unstructured":"Hassan S, Baccarelli A et al (2008) Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res 14(2):446\u2013454","journal-title":"Clin Cancer Res"},{"issue":"1","key":"117_CR75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2353\/ajpath.2009.080948","volume":"175","author":"S Hassan","year":"2009","unstructured":"Hassan S, Ferrario C et al (2009) The influence of tumor-host interactions in the stromal cell-derived factor-1\/CXCR4 ligand\/receptor axis in determining metastatic risk in breast cancer. Am J Pathol 175(1):66\u201373","journal-title":"Am J Pathol"},{"key":"117_CR76","doi-asserted-by":"crossref","unstructured":"Hassan S, Buchanan M, et al (2010) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer","DOI":"10.1002\/ijc.25665"},{"issue":"4","key":"117_CR77","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-05-2814","volume":"66","author":"MA Henderson","year":"2006","unstructured":"Henderson MA, Danks JA et al (2006) Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 66(4):2250\u20132256","journal-title":"Cancer Res"},{"issue":"29","key":"117_CR78","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McMahon DJ et al (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26(29):4739\u20134745","journal-title":"J Clin Oncol"},{"issue":"2","key":"117_CR79","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","volume":"95","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, McMahon DJ et al (2010) Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 95(2):559\u2013566","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"117_CR80","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess KR, Varadhachary GR et al (2006) Metastatic patterns in adenocarcinoma. Cancer 106(7):1624\u20131633","journal-title":"Cancer"},{"issue":"13","key":"117_CR81","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","volume":"10","author":"T Hiraga","year":"2004","unstructured":"Hiraga T, Williams PJ et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model. Clin Cancer Res 10(13):4559\u20134567","journal-title":"Clin Cancer Res"},{"issue":"12","key":"117_CR82","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.ejca.2010.04.012","volume":"46","author":"S Hiscox","year":"2010","unstructured":"Hiscox S, Barrett-Lee P et al (2010) Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer 46(12):2187\u20132195","journal-title":"Eur J Cancer"},{"issue":"3","key":"117_CR83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10549-005-2419-8","volume":"92","author":"I Holen","year":"2005","unstructured":"Holen I, Cross SS et al (2005) Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo\u2014a role in tumour cell survival? Breast Cancer Res Treat 92(3):207\u2013215","journal-title":"Breast Cancer Res Treat"},{"key":"117_CR84","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.0105-2896.2005.00335.x","volume":"208","author":"WC Horne","year":"2005","unstructured":"Horne WC, Sanjay A et al (2005) The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 208:106\u2013125","journal-title":"Immunol Rev"},{"issue":"12","key":"117_CR85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1359-6349(08)72339-5","volume":"6","author":"SJ Hotte","year":"2008","unstructured":"Hotte SJ, Hirte HW et al (2008) 405 POSTER Final results of a Phase I\/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Eur J Cancer Suppl 6(12):127\u2013127","journal-title":"Eur J Cancer Suppl"},{"issue":"2","key":"117_CR86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2008.06.044","volume":"155","author":"EH Huang","year":"2009","unstructured":"Huang EH, Singh B et al (2009) A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231\u2013236","journal-title":"J Surg Res"},{"issue":"2","key":"117_CR87","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jcp.21223","volume":"213","author":"H Hugo","year":"2007","unstructured":"Hugo H, Ackland ML et al (2007) Epithelial\u2013mesenchymal and mesenchymal\u2013epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374\u2013383","journal-title":"J Cell Physiol"},{"key":"117_CR88","doi-asserted-by":"crossref","unstructured":"Hussein O, Tiedemann K, et al (2010) Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis. Bone 48:202\u2013211","DOI":"10.1016\/j.bone.2010.09.006"},{"key":"117_CR89","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2407-10-298","volume":"10","author":"H Id Boufker","year":"2010","unstructured":"Id Boufker H, Lagneaux L et al (2010) The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 10:298","journal-title":"BMC Cancer"},{"issue":"11","key":"117_CR90","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nm1197-1285","volume":"3","author":"V Iotsova","year":"1997","unstructured":"Iotsova V, Caamano J et al (1997) Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3(11):1285\u20131289","journal-title":"Nat Med"},{"issue":"7084","key":"117_CR91","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","volume":"440","author":"DH Jones","year":"2006","unstructured":"Jones DH, Nakashima T et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084):692\u2013696","journal-title":"Nature"},{"issue":"5","key":"117_CR92","doi-asserted-by":"crossref","first-page":"E210","DOI":"10.25011\/cim.v30i5.2897","volume":"30","author":"RG Josse","year":"2007","unstructured":"Josse RG, Hanley DA et al (2007) Diagnosis and treatment of Paget\u2019s disease of bone. Clin Invest Med 30(5):E210\u2013E223","journal-title":"Clin Invest Med"},{"issue":"3 Suppl","key":"117_CR93","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/cncr.11132","volume":"97","author":"SM Kakonen","year":"2003","unstructured":"Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(3 Suppl):834\u2013839","journal-title":"Cancer"},{"issue":"6","key":"117_CR94","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","volume":"3","author":"Y Kang","year":"2003","unstructured":"Kang Y, Siegel PM et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537\u2013549","journal-title":"Cancer Cell"},{"issue":"4","key":"117_CR95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nri2279","volume":"8","author":"MJ Kiel","year":"2008","unstructured":"Kiel MJ, Morrison SJ (2008) Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 8(4):290\u2013301","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"117_CR96","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yexcr.2007.09.021","volume":"314","author":"M Kinder","year":"2008","unstructured":"Kinder M, Chislock E et al (2008a) Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 314(1):173\u2013183","journal-title":"Exp Cell Res"},{"issue":"1","key":"117_CR97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yexcr.2007.09.021","volume":"314","author":"M Kinder","year":"2008","unstructured":"Kinder M, Chislock E et al (2008b) Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 314(1):173\u2013183","journal-title":"Exp Cell Res"},{"issue":"2","key":"117_CR98","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","volume":"198","author":"S Kitazawa","year":"2002","unstructured":"Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198(2):228\u2013236","journal-title":"J Pathol"},{"issue":"2","key":"117_CR99","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2008.11.017","volume":"276","author":"A Klein","year":"2009","unstructured":"Klein A, Olendrowitz C et al (2009) Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 276(2):212\u2013220","journal-title":"Cancer Lett"},{"issue":"3","key":"117_CR100","first-page":"337","volume":"24","author":"HJ Knowles","year":"2009","unstructured":"Knowles HJ, Athanasou NA (2009) Canonical and non-canonical pathways of osteoclast formation. Histol Histopathol 24(3):337\u2013346","journal-title":"Histol Histopathol"},{"issue":"5","key":"117_CR101","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.173.5.1291","volume":"173","author":"H Kodama","year":"1991","unstructured":"Kodama H, Nose M et al (1991) Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 173(5):1291\u20131294","journal-title":"J Exp Med"},{"issue":"6984","key":"117_CR102","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature02444","volume":"428","author":"T Koga","year":"2004","unstructured":"Koga T, Inui M et al (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428(6984):758\u2013763","journal-title":"Nature"},{"issue":"15","key":"117_CR103","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314\u20133321","journal-title":"J Clin Oncol"},{"issue":"6","key":"117_CR104","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nm1417","volume":"12","author":"O Kollet","year":"2006","unstructured":"Kollet O, Dar A et al (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12(6):657\u2013664","journal-title":"Nat Med"},{"key":"117_CR105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.immunol.25.022106.141631","volume":"25","author":"O Kollet","year":"2007","unstructured":"Kollet O, Dar A et al (2007) The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 25:51\u201369","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"117_CR106","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1080\/14653240802419328","volume":"10","author":"M Kondo","year":"2008","unstructured":"Kondo M, Sakuta K et al (2008) Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10(8):842\u2013856","journal-title":"Cytotherapy"},{"issue":"6717","key":"117_CR107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong YY, Yoshida H et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397(6717):315\u2013323","journal-title":"Nature"},{"issue":"1","key":"117_CR108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10459-004-6006-2","volume":"88","author":"R Korah","year":"2004","unstructured":"Korah R, Choi L et al (2004) Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 88(1):17\u201328","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"117_CR109","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","volume":"10","author":"W Kozlow","year":"2005","unstructured":"Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10(2):169\u2013180","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"28","key":"117_CR110","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","volume":"26","author":"A Kyrgidis","year":"2008","unstructured":"Kyrgidis A, Vahtsevanos K et al (2008) Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26(28):4634\u20134638","journal-title":"J Clin Oncol"},{"issue":"2","key":"117_CR111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W","volume":"33","author":"PT Lakkakorpi","year":"1996","unstructured":"Lakkakorpi PT, Vaananen HK (1996) Cytoskeletal changes in osteoclasts during the resorption cycle. Microsc Res Tech 33(2):171\u2013181","journal-title":"Microsc Res Tech"},{"issue":"20","key":"117_CR112","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","volume":"67","author":"C Gall Le","year":"2007","unstructured":"Le Gall C, Bellahcene A et al (2007) A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 67(20):9894\u20139902","journal-title":"Cancer Res"},{"issue":"3","key":"117_CR113","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jso.2930230311","volume":"23","author":"YT Lee","year":"1983","unstructured":"Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23(3):175\u2013180","journal-title":"J Surg Oncol"},{"issue":"22","key":"117_CR114","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/onc.2010.73","volume":"29","author":"YC Lee","year":"2010","unstructured":"Lee YC, Huang CF et al (2010) Src family kinase\/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22):3196\u20133207","journal-title":"Oncogene"},{"issue":"6","key":"117_CR115","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00000421-198812000-00004","volume":"11","author":"BA Leone","year":"1988","unstructured":"Leone BA, Romero A et al (1988) Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol 11(6):618\u2013622","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"117_CR116","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1098-3597(06)80064-5","volume":"8","author":"JP Levine","year":"2006","unstructured":"Levine JP (2006) Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 8(1):40\u201353","journal-title":"Clin Cornerstone"},{"issue":"4","key":"117_CR117","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10585-007-9117-3","volume":"25","author":"Z Li","year":"2008","unstructured":"Li Z, Schem C et al (2008) Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis 25(4):389\u2013400","journal-title":"Clin Exp Metastasis"},{"issue":"20 Pt 2","key":"117_CR118","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","volume":"12","author":"A Lipton","year":"2006","unstructured":"Lipton A (2006) Future treatment of bone metastases. Clin Cancer Res 12(20 Pt 2):6305s\u20136308s","journal-title":"Clin Cancer Res"},{"issue":"9","key":"117_CR119","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","volume":"12","author":"A Lipton","year":"2007","unstructured":"Lipton A, Cook RJ et al (2007a) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12(9):1035\u20131043","journal-title":"Oncologist"},{"issue":"28","key":"117_CR120","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"A Lipton","year":"2007","unstructured":"Lipton A, Steger GG et al (2007b) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25(28):4431\u20134437","journal-title":"J Clin Oncol"},{"issue":"20","key":"117_CR121","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","volume":"14","author":"A Lipton","year":"2008","unstructured":"Lipton A, Steger GG et al (2008) Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14(20):6690\u20136696","journal-title":"Clin Cancer Res"},{"issue":"1","key":"117_CR122","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","volume":"100","author":"AT Mancino","year":"2001","unstructured":"Mancino AT, Klimberg VS et al (2001) Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100(1):18\u201324","journal-title":"J Surg Res"},{"issue":"2","key":"117_CR123","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.abb.2008.03.027","volume":"473","author":"K Matsuo","year":"2008","unstructured":"Matsuo K, Irie N (2008) Osteoclast-osteoblast communication. Arch Biochem Biophys 473(2):201\u2013209","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"117_CR124","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1172\/JCI8905","volume":"105","author":"KP McHugh","year":"2000","unstructured":"McHugh KP, Hodivala-Dilke K et al (2000) Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105(4):433\u2013440","journal-title":"J Clin Invest"},{"issue":"3\u20134","key":"117_CR125","first-page":"184","volume":"36","author":"B McMahon","year":"2008","unstructured":"McMahon B, Kwaan HC (2008) The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 36(3\u20134):184\u2013194","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"7308","key":"117_CR126","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09262","volume":"466","author":"S Mendez-Ferrer","year":"2010","unstructured":"Mendez-Ferrer S, Michurina TV et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829\u2013834","journal-title":"Nature"},{"issue":"2","key":"117_CR127","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","volume":"161","author":"S Meraviglia","year":"2010","unstructured":"Meraviglia S, Eberl M et al (2010) In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161(2):290\u2013297","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"117_CR128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1172\/JCI22320","volume":"115","author":"AJ Minn","year":"2005","unstructured":"Minn AJ, Kang Y et al (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115(1):44\u201355","journal-title":"J Clin Invest"},{"issue":"6","key":"117_CR129","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1600-0609.2010.01419.x","volume":"84","author":"S Mishima","year":"2010","unstructured":"Mishima S, Nagai A et al (2010) Effective ex vivo expansion of hematopoietic stem cells using osteoblast-differentiated mesenchymal stem cells is CXCL12 dependent. Eur J Haematol 84(6):538\u2013546","journal-title":"Eur J Haematol"},{"issue":"2","key":"117_CR130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10165-006-0460-z","volume":"16","author":"T Miyazaki","year":"2006","unstructured":"Miyazaki T, Tanaka S et al (2006) The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 16(2):68\u201374","journal-title":"Mod Rheumatol"},{"issue":"16","key":"117_CR131","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1073\/pnas.0401602101","volume":"101","author":"A Mocsai","year":"2004","unstructured":"Mocsai A, Humphrey MB et al (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101(16):6158\u20136163","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"117_CR132","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ijc.20056","volume":"109","author":"H Morgan","year":"2004","unstructured":"Morgan H, Tumber A et al (2004) Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte\/macrophage colony-stimulating factor. Int J Cancer 109(5):653\u2013660","journal-title":"Int J Cancer"},{"issue":"2","key":"117_CR133","first-page":"235","volume":"24","author":"K Mori","year":"2009","unstructured":"Mori K, Ando K et al (2009) Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histol Histopathol 24(2):235\u2013242","journal-title":"Histol Histopathol"},{"issue":"5","key":"117_CR134","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/187152007781668689","volume":"7","author":"AA Mourskaia","year":"2007","unstructured":"Mourskaia AA, Northey JJ et al (2007) Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med Chem 7(5):504\u2013514","journal-title":"Anticancer Agents Med Chem"},{"issue":"7","key":"117_CR135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/onc.2008.454","volume":"28","author":"AA Mourskaia","year":"2009","unstructured":"Mourskaia AA, Dong Z et al (2009) Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 28(7):1005\u20131015","journal-title":"Oncogene"},{"issue":"6","key":"117_CR136","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jemt.10371","volume":"61","author":"M Mulari","year":"2003","unstructured":"Mulari M, Vaaraniemi J et al (2003) Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech 61(6):496\u2013503","journal-title":"Microsc Res Tech"},{"issue":"6824","key":"117_CR137","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A Muller","year":"2001","unstructured":"Muller A, Homey B et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50\u201356","journal-title":"Nature"},{"issue":"8 Suppl","key":"117_CR138","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","volume":"80","author":"GR Mundy","year":"1997","unstructured":"Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80(8 Suppl):1546\u20131556","journal-title":"Cancer"},{"issue":"6","key":"117_CR139","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2443.1999.00265.x","volume":"4","author":"A Naito","year":"1999","unstructured":"Naito A, Azuma S et al (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4(6):353\u2013362","journal-title":"Genes Cells"},{"issue":"5","key":"117_CR140","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-04-1083","volume":"11","author":"S Najmi","year":"2005","unstructured":"Najmi S, Korah R et al (2005) Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin Cancer Res 11(5):2038\u20132046","journal-title":"Clin Cancer Res"},{"issue":"6","key":"117_CR141","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jmicro\/52.6.527","volume":"52","author":"I Nakamura","year":"2003","unstructured":"Nakamura I, Rodan GA et al (2003) Regulatory mechanism of osteoclast activation. J Electron Microsc (Tokyo) 52(6):527\u2013533","journal-title":"J Electron Microsc (Tokyo)"},{"issue":"6","key":"117_CR142","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-007-0773-9","volume":"25","author":"I Nakamura","year":"2007","unstructured":"Nakamura I, Duong le T et al (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25(6):337\u2013344","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"117_CR143","first-page":"248","volume":"12","author":"L Naumovski","year":"2010","unstructured":"Naumovski L, Junutula JR (2010) Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12(2):248\u2013257","journal-title":"Curr Opin Mol Ther"},{"issue":"2","key":"117_CR144","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2009.03.035","volume":"283","author":"J Nautiyal","year":"2009","unstructured":"Nautiyal J, Majumder P et al (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 283(2):143\u2013151","journal-title":"Cancer Lett"},{"issue":"1","key":"117_CR145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","volume":"231","author":"T Negishi-Koga","year":"2009","unstructured":"Negishi-Koga T, Takayanagi H (2009) Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 231(1):241\u2013256","journal-title":"Immunol Rev"},{"issue":"3","key":"117_CR146","first-page":"269","volume":"86","author":"HL Neville-Webbe","year":"2004","unstructured":"Neville-Webbe HL, Cross NA et al (2004) Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 86(3):269\u2013279","journal-title":"Breast Cancer Res Treat"},{"key":"117_CR147","doi-asserted-by":"crossref","unstructured":"Onishi T, Hayashi N, et al (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol","DOI":"10.1038\/nrclinonc.2010.134"},{"issue":"8\u20139","key":"117_CR148","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ejcb.2008.03.002","volume":"87","author":"S Ory","year":"2008","unstructured":"Ory S, Brazier H et al (2008) Rho GTPases in osteoclasts: orchestrators of podosome arrangement. Eur J Cell Biol 87(8\u20139):469\u2013477","journal-title":"Eur J Cell Biol"},{"issue":"16","key":"117_CR149","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","volume":"100","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, Monkkonen H et al (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100(16):1167\u20131178","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"117_CR150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm1519","volume":"13","author":"BK Park","year":"2007","unstructured":"Park BK, Zhang H et al (2007) NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13(1):62\u201369","journal-title":"Nat Med"},{"issue":"2\u20133","key":"117_CR151","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1023047431869","volume":"22","author":"M Pavlaki","year":"2003","unstructured":"Pavlaki M, Zucker S (2003) Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22(2\u20133):177\u2013203","journal-title":"Cancer Metastasis Rev"},{"issue":"6797","key":"117_CR152","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"5","key":"117_CR153","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-05-1806","volume":"12","author":"PA Phadke","year":"2006","unstructured":"Phadke PA, Mercer RR et al (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12(5):1431\u20131440","journal-title":"Clin Cancer Res"},{"issue":"1","key":"117_CR154","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.bjc.6605101","volume":"101","author":"CS Pichot","year":"2009","unstructured":"Pichot CS, Hartig SM et al (2009) Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101(1):38\u201347","journal-title":"Br J Cancer"},{"issue":"11","key":"117_CR155","first-page":"3059","volume":"51","author":"GJ Powell","year":"1991","unstructured":"Powell GJ, Southby J et al (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51(11):3059\u20133061","journal-title":"Cancer Res"},{"issue":"1","key":"117_CR156","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jcb.22232","volume":"108","author":"TD Rachner","year":"2009","unstructured":"Rachner TD, Benad P et al (2009) Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 108(1):106\u2013116","journal-title":"J Cell Biochem"},{"issue":"5","key":"117_CR157","first-page":"1807","volume":"30","author":"B Rack","year":"2010","unstructured":"Rack B, Juckstock J et al (2010) Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 30(5):1807\u20131813","journal-title":"Anticancer Res"},{"issue":"2","key":"117_CR158","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1359\/jbmr.2003.18.2.190","volume":"18","author":"AH Reddi","year":"2003","unstructured":"Reddi AH, Roodman D et al (2003) Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18(2):190\u2013194","journal-title":"J Bone Miner Res"},{"issue":"3","key":"117_CR159","first-page":"761","volume":"21","author":"MM Richert","year":"2009","unstructured":"Richert MM, Vaidya KS et al (2009) Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21(3):761\u2013767","journal-title":"Oncol Rep"},{"issue":"10","key":"117_CR160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1541-7786.MCR-07-0119","volume":"5","author":"AA Rose","year":"2007","unstructured":"Rose AA, Pepin F et al (2007) Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5(10):1001\u20131014","journal-title":"Mol Cancer Res"},{"issue":"1","key":"117_CR161","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/fon.09.138","volume":"6","author":"AA Rose","year":"2010","unstructured":"Rose AA, Siegel PM (2010) Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6(1):55\u201374","journal-title":"Future Oncol"},{"issue":"7","key":"117_CR162","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-09-1611","volume":"16","author":"AA Rose","year":"2010","unstructured":"Rose AA, Grosset AA et al (2010) Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16(7):2147\u20132156","journal-title":"Clin Cancer Res"},{"issue":"8","key":"117_CR163","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735\u20131744","journal-title":"Cancer"},{"issue":"1","key":"117_CR164","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1):36\u201343","journal-title":"Cancer"},{"issue":"Suppl 2","key":"117_CR165","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","volume":"119","author":"RG Russell","year":"2007","unstructured":"Russell RG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2):S150\u2013S162","journal-title":"Pediatrics"},{"issue":"2","key":"117_CR166","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2009.11.005","volume":"36","author":"F Saad","year":"2010","unstructured":"Saad F, Lipton A (2010) SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36(2):177\u2013184","journal-title":"Cancer Treat Rev"},{"issue":"8\u20139","key":"117_CR167","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejcb.2008.01.001","volume":"87","author":"F Saltel","year":"2008","unstructured":"Saltel F, Chabadel A et al (2008) Actin cytoskeletal organisation in osteoclasts: a model to decipher transmigration and matrix degradation. Eur J Cell Biol 87(8\u20139):459\u2013468","journal-title":"Eur J Cell Biol"},{"issue":"15 Pt 1","key":"117_CR168","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","volume":"13","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13(15 Pt 1):4482\u20134486","journal-title":"Clin Cancer Res"},{"key":"117_CR169","doi-asserted-by":"crossref","unstructured":"Santini D, Perrone G, et al (2010) Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol","DOI":"10.1002\/jcp.22402"},{"issue":"4","key":"117_CR170","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/en.2004-1211","volume":"146","author":"A Schneider","year":"2005","unstructured":"Schneider A, Kalikin LM et al (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146(4):1727\u20131736","journal-title":"Endocrinology"},{"issue":"6","key":"117_CR171","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/09513590802095845","volume":"24","author":"A Schubert","year":"2008","unstructured":"Schubert A, Schulz H et al (2008) Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression. Gynecol Endocrinol 24(6):331\u2013338","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"117_CR172","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/1097-0142(19860701)58:1<178::AID-CNCR2820580130>3.0.CO;2-T","volume":"58","author":"MM Sherry","year":"1986","unstructured":"Sherry MM, Greco FA et al (1986a) Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 58(1):178\u2013182","journal-title":"Cancer"},{"issue":"3","key":"117_CR173","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0002-9343(86)90286-X","volume":"81","author":"MM Sherry","year":"1986","unstructured":"Sherry MM, Greco FA et al (1986b) Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 81(3):381\u2013386","journal-title":"Am J Med"},{"issue":"7","key":"117_CR174","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1359\/jbmr.060416","volume":"21","author":"T Shimo","year":"2006","unstructured":"Shimo T, Kubota S et al (2006) Pathogenic role of connective tissue growth factor (CTGF\/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21(7):1045\u20131059","journal-title":"J Bone Miner Res"},{"issue":"4","key":"117_CR175","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10555-006-9023-1","volume":"25","author":"VA Siclari","year":"2006","unstructured":"Siclari VA, Guise TA et al (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25(4):621\u2013633","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"117_CR176","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jss.2006.03.018","volume":"134","author":"B Singh","year":"2006","unstructured":"Singh B, Berry JA et al (2006) Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res 134(1):44\u201351","journal-title":"J Surg Res"},{"issue":"1","key":"117_CR177","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ncponc0685","volume":"4","author":"MJ Slade","year":"2007","unstructured":"Slade MJ, Coombes RC (2007) The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 4(1):30\u201341","journal-title":"Nat Clin Pract Oncol"},{"issue":"15","key":"117_CR178","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.2005.03.8802","volume":"24","author":"M Smid","year":"2006","unstructured":"Smid M, Wang Y et al (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24(15):2261\u20132267","journal-title":"J Clin Oncol"},{"issue":"9","key":"117_CR179","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","volume":"68","author":"M Smid","year":"2008","unstructured":"Smid M, Wang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68(9):3108\u20133114","journal-title":"Cancer Res"},{"issue":"3","key":"117_CR180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006308619659","volume":"59","author":"EF Solomayer","year":"2000","unstructured":"Solomayer EF, Diel IJ et al (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271\u2013278","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"117_CR181","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","volume":"64","author":"P Soriano","year":"1991","unstructured":"Soriano P, Montgomery C et al (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64(4):693\u2013702","journal-title":"Cell"},{"issue":"19","key":"117_CR182","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869\u201310874","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"117_CR183","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418\u20138423","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"117_CR184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10266-007-0071-y","volume":"95","author":"N Takahashi","year":"2007","unstructured":"Takahashi N, Ejiri S et al (2007) Regulation of osteoclast polarization. Odontology 95(1):1\u20139","journal-title":"Odontology"},{"issue":"48","key":"117_CR185","doi-asserted-by":"crossref","first-page":"33662","DOI":"10.1074\/jbc.M109.010785","volume":"284","author":"K Tiedemann","year":"2009","unstructured":"Tiedemann K, Hussein O et al (2009) Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+\/protein kinase C and transforming growth factor-beta\/MAPK signaling pathways. J Biol Chem 284(48):33662\u201333670","journal-title":"J Biol Chem"},{"issue":"5","key":"117_CR186","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3816\/CBC.2010.n.050","volume":"10","author":"K Tjensvoll","year":"2010","unstructured":"Tjensvoll K, Oltedal S et al (2010) Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. Clin Breast Cancer 10(5):378\u2013384","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"117_CR187","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/bcr2416","volume":"11","author":"E Tomaskovic-Crook","year":"2009","unstructured":"Tomaskovic-Crook E, Thompson EW et al (2009) Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 11(6):213","journal-title":"Breast Cancer Res"},{"issue":"6620","key":"117_CR188","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/386081a0","volume":"386","author":"MM Tondravi","year":"1997","unstructured":"Tondravi MM, McKercher SR et al (1997) Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 386(6620):81\u201384","journal-title":"Nature"},{"issue":"3","key":"117_CR189","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/0008-5472.CAN-07-2148","volume":"68","author":"AJ Trimboli","year":"2008","unstructured":"Trimboli AJ, Fukino K et al (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68(3):937\u2013945","journal-title":"Cancer Res"},{"issue":"5\u20136","key":"117_CR190","first-page":"193","volume":"77","author":"HK Vaananen","year":"1988","unstructured":"Vaananen HK, Hentunen T et al (1988) Mechanism of osteoclast mediated bone resorption. Ann Chir Gynaecol 77(5\u20136):193\u2013196","journal-title":"Ann Chir Gynaecol"},{"issue":"2","key":"117_CR191","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2008.03.037","volume":"473","author":"HK Vaananen","year":"2008","unstructured":"Vaananen HK, Laitala-Leinonen T (2008) Osteoclast lineage and function. Arch Biochem Biophys 473(2):132\u2013138","journal-title":"Arch Biochem Biophys"},{"issue":"Pt 3","key":"117_CR192","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1242\/jcs.113.3.377","volume":"113","author":"HK Vaananen","year":"2000","unstructured":"Vaananen HK, Zhao H et al (2000) The cell biology of osteoclast function. J Cell Sci 113(Pt 3):377\u2013381","journal-title":"J Cell Sci"},{"issue":"6871","key":"117_CR193","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ Veer van \u2019t","year":"2002","unstructured":"van \u2019t Veer LJ, Dai H et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530\u2013536","journal-title":"Nature"},{"issue":"25","key":"117_CR194","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Vijver van de","year":"2002","unstructured":"van de Vijver MJ, He YD et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999\u20132009","journal-title":"N Engl J Med"},{"issue":"6","key":"117_CR195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0609.2006.00633.x","volume":"76","author":"N Overstraeten-Schlogel Van","year":"2006","unstructured":"Van Overstraeten-Schlogel N, Beguin Y et al (2006) Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. Eur J Haematol 76(6):488\u2013493","journal-title":"Eur J Haematol"},{"issue":"9","key":"117_CR196","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","volume":"21","author":"I Metzler von","year":"2007","unstructured":"von Metzler I, Krebbel H et al (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21(9):2025\u20132034","journal-title":"Leukemia"},{"issue":"1","key":"117_CR197","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada T, Nakashima T et al (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12(1):17\u201325","journal-title":"Trends Mol Med"},{"issue":"9460","key":"117_CR198","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(05)17947-1","volume":"365","author":"Y Wang","year":"2005","unstructured":"Wang Y, Klijn JG et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671\u2013679","journal-title":"Lancet"},{"issue":"4","key":"117_CR199","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10555-006-9019-x","volume":"25","author":"J Wang","year":"2006","unstructured":"Wang J, Loberg R et al (2006) The pivotal role of CXCL12 (SDF-1)\/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25(4):573\u2013587","journal-title":"Cancer Metastasis Rev"},{"issue":"6406","key":"117_CR200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/360741a0","volume":"360","author":"ZQ Wang","year":"1992","unstructured":"Wang ZQ, Ovitt C et al (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360(6406):741\u2013745","journal-title":"Nature"},{"issue":"3","key":"117_CR201","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00132751","volume":"10","author":"L Weiss","year":"1992","unstructured":"Weiss L (1992) Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis 10(3):191\u2013199","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"117_CR202","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1073\/pnas.87.12.4828","volume":"87","author":"W Wiktor-Jedrzejczak","year":"1990","unstructured":"Wiktor-Jedrzejczak W, Bartocci A et al (1990) Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op\/op) mouse. Proc Natl Acad Sci USA 87(12):4828\u20134832","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"117_CR203","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1158\/1078-0432.CCR-05-0632","volume":"11","author":"B Willipinski-Stapelfeldt","year":"2005","unstructured":"Willipinski-Stapelfeldt B, Riethdorf S et al (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11(22):8006\u20138014","journal-title":"Clin Cancer Res"},{"issue":"14","key":"117_CR204","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1158\/0008-5472.CAN-07-5889","volume":"68","author":"TJ Wilson","year":"2008","unstructured":"Wilson TJ, Nannuru KC et al (2008) Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 68(14):5803\u20135811","journal-title":"Cancer Res"},{"issue":"7","key":"117_CR205","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-08-1956","volume":"69","author":"TJ Wilson","year":"2009","unstructured":"Wilson TJ, Nannuru KC et al (2009) Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1. Cancer Res 69(7):3188\u20133195","journal-title":"Cancer Res"},{"issue":"22","key":"117_CR206","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1158\/0008-5472.CAN-08-2556","volume":"68","author":"L Yang","year":"2008","unstructured":"Yang L, Moses HL (2008) Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 68(22):9107\u20139111","journal-title":"Cancer Res"},{"issue":"2","key":"117_CR207","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin JJ, Selander K et al (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103(2):197\u2013206","journal-title":"J Clin Invest"},{"issue":"6","key":"117_CR208","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.leukres.2009.08.034","volume":"34","author":"A Yokota","year":"2010","unstructured":"Yokota A, Kimura S et al (2010) Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res 34(6):793\u2013799","journal-title":"Leuk Res"},{"issue":"6","key":"117_CR209","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1113\/expphysiol.1993.sp003721","volume":"78","author":"M Zaidi","year":"1993","unstructured":"Zaidi M, Pazianas M et al (1993) Osteoclast function and its control. Exp Physiol 78(6):721\u2013739","journal-title":"Exp Physiol"},{"issue":"1","key":"117_CR210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","volume":"16","author":"XH Zhang","year":"2009","unstructured":"Zhang XH, Wang Q et al (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16(1):67\u201378","journal-title":"Cancer Cell"},{"issue":"5","key":"117_CR211","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2008-0227","volume":"14","author":"M Zuradelli","year":"2009","unstructured":"Zuradelli M, Masci G et al (2009) High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. Oncologist 14(5):548\u2013556","journal-title":"Oncologist"}],"container-title":["Journal of Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12079-011-0117-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12079-011-0117-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12079-011-0117-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:26:22Z","timestamp":1712125582000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12079-011-0117-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":211,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1007\/s12079-011-0117-3","relation":{},"ISSN":["1873-9601","1873-961X"],"issn-type":[{"value":"1873-9601","type":"print"},{"value":"1873-961X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,19]]}}}